Johnson Dermatology | Fort Smith, AR

Research site

(Unclaimed)

Location

5921 Riley Park Drive, Fort Smith, Arkansas, United States of America

Site insights

Top conditions

Top treatments

JNJ-77242113

LY3009104

Baricitinib

BMS-986165

CB-03-01

Ixekizumab

Zasocitinib

Deucravacitinib

LY3454738

CTP-543

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 40 total trials

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo 1

Drug: Placebo 2

Locations recently updated

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting

Plaque Psoriasis

Drug: Deucravacitinib Matching Placebo

Drug: JNJ-77242113 Matching Placebo

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting

Plaque Psoriasis

Drug: Placebo

Drug: JNJ-77242113

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting

Plaque Psoriasis

Drug: JNJ-77242113

Drug: Placebo

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin r...

Enrolling

Hidradenitis Suppurativa

Drug: Zasocitinib (Dose A)

Other: Placebo

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate...

Enrolling

Hidradenitis Suppurativa

Drug: Remibrutinib

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543